Cannabis Rescheduling Hearings Could Reshape the U.S. Marijuana Industry
For more than fifty years, cannabis has remained classified as a Schedule I controlled substance under the federal Controlled Substances Act, a designation reserved for drugs considered to have a high potential for abuse and no currently accepted medical use. Today, that classification is facing its most significant legal and regulatory challenge in decades.
The U.S. Drug Enforcement Administration (DEA) is conducting administrative hearings to determine whether marijuana should be transferred from Schedule I to Schedule III following a recommendation from the U.S. Department of Health and Human Services (HHS). The recommendation followed an extensive scientific and medical review requested by the White House.
If ultimately approved, the move would represent one of the most consequential federal cannabis policy changes in modern American history. While rescheduling would not federally legalize recreational marijuana, industry experts believe it could fundamentally alter taxation, research, investment opportunities, physician prescribing practices, and the relationship between state-regulated cannabis businesses and the federal government.
Yet the proposal has also generated significant opposition from public health advocates, anti-legalization organizations, former DEA officials, and lawmakers who argue that the scientific evidence does not justify easing federal restrictions.
As the hearings continue, stakeholders from across the political spectrum are watching closely.
Understanding Cannabis Rescheduling
Under the Controlled Substances Act, drugs are categorized into five schedules based on medical use, abuse potential, and safety.
Schedule I currently includes substances such as heroin and LSD, while Schedule III includes medications recognized for accepted medical uses and moderate to low potential for physical dependence. Moving cannabis to Schedule III would acknowledge accepted medical use under federal law while maintaining federal regulation through the DEA and the Food and Drug Administration (FDA). Importantly, rescheduling is not the same as legalization.
Even if cannabis is transferred to Schedule III:
- Adult-use marijuana would remain federally illegal.
- Interstate transportation of cannabis products would remain prohibited without additional congressional action.
- Individual state cannabis programs would continue operating under their own laws.
- Federal criminal penalties for unauthorized distribution would still exist.
Instead, experts describe rescheduling as an administrative regulatory change rather than comprehensive cannabis reform.
Why the Hearings Matter
The DEA’s administrative hearing process allows scientific experts, medical professionals, regulators, attorneys, advocacy organizations, and interested parties to present evidence supporting or opposing the proposed rule.
Administrative Law Judges will evaluate:
- Scientific evidence
- Medical research
- Public health concerns
- Abuse potential
- Federal regulatory authority
- Existing state medical cannabis programs
The hearings could influence whether the DEA ultimately adopts, modifies, or rejects the HHS recommendation.
While the agency is not legally required to follow every recommendation submitted during the hearing process, testimony becomes part of the official administrative record used to justify any final rule.
Cannabis Industry Leaders See a Historic Opportunity
Many leaders within the legal cannabis industry argue that rescheduling reflects decades of evolving scientific evidence and growing public acceptance.
Executives from multi-state operators (MSOs), independent dispensaries, cultivators, pharmaceutical developers, and ancillary businesses have largely welcomed the proposal.
Their optimism centers on several major areas.
Relief from IRS Section 280E
Perhaps the most immediate financial impact would involve Internal Revenue Code Section 280E. Currently, because cannabis remains a Schedule I controlled substance, licensed marijuana businesses cannot deduct most ordinary business expenses. Unlike nearly every other American business, cannabis operators often pay effective tax rates exceeding 60 percent. Removing marijuana from Schedule I could eliminate the application of Section 280E to state-licensed cannabis businesses, dramatically reducing federal tax burdens.
Accounting firms serving the cannabis industry estimate that billions of dollars could remain within businesses annually through legitimate operating deductions. For many operators struggling with compressed margins, increased competition, and declining wholesale prices, those tax savings could prove transformative.
Greater Investment Interest
Institutional investors have historically remained cautious due to the ongoing federal prohibition.
Investment analysts suggest that rescheduling could improve confidence among:
- Private equity firms
- Venture capital funds
- Commercial lenders
- Institutional investors
- Public market participants
Although banking reforms would still require congressional action, reduced regulatory uncertainty may encourage greater capital investment throughout the industry.
Expanded Medical Research
Researchers have long argued that Schedule I classification creates unnecessary administrative barriers.
Universities frequently cite:
- lengthy DEA registration requirements
- limited federally approved research material
- extensive compliance procedures
Medical researchers believe Schedule III status could streamline portions of the research process while encouraging additional clinical studies involving cannabinoid therapies.
Potential research areas include:
- chronic pain
- epilepsy
- PTSD
- multiple sclerosis
- inflammatory disorders
- cancer symptom management
- neurodegenerative diseases
Many physicians emphasize that additional research, not less oversight, remains the primary objective.
Legal Experts Describe Rescheduling as an Important, but Limited Step
Cannabis attorneys generally caution against viewing Schedule III as the finish line. Federal law would continue prohibiting commercial marijuana outside federally authorized channels. Attorneys note that state-licensed businesses would still operate within a legal gray area.
Questions remain regarding:
- interstate commerce
- FDA oversight
- labeling requirements
- manufacturing standards
- pharmaceutical development
- employment law
- firearms ownership
- immigration consequences
Many legal analysts expect additional litigation regardless of the DEA’s final decision.
Several experts predict Congress will eventually need to clarify the relationship between state cannabis markets and federal law to eliminate ongoing legal uncertainty.
Public Health Experts Offer Qualified Support
Some physicians and addiction specialists support rescheduling because they believe current federal classifications no longer accurately reflect available scientific evidence. These experts emphasize that acknowledging accepted medical use does not mean cannabis is harmless.
They continue recommending:
- physician supervision
- age restrictions
- product testing
- potency labeling
- impaired driving enforcement
- public education campaigns
Medical organizations generally advocate balancing expanded patient access with evidence-based regulation rather than complete deregulation.
That distinction has become a recurring theme throughout the ongoing hearings.
Opposition Voices Raise Concerns About Rescheduling Cannabis
While much of the legal cannabis industry has welcomed the proposed move to Schedule III, the hearings have also highlighted concerns from organizations, policymakers, physicians, and former federal officials who believe the change could create unintended public health and regulatory consequences. Rather than arguing that cannabis should remain permanently prohibited, many opponents contend that the scientific evidence has not yet met the legal standards required under the Controlled Substances Act for rescheduling.
Among the most prominent critics is Smart Approaches to Marijuana (SAM), a national organization that advocates against commercial marijuana legalization while supporting research into cannabis-derived medicines approved through the U.S. Food and Drug Administration (FDA). SAM leaders have argued that many existing studies demonstrate therapeutic potential for specific cannabinoids but do not necessarily justify broad federal recognition of cannabis as an accepted medicine. The organization has also expressed concern that rescheduling could accelerate commercialization before additional long-term safety data are available.
Several addiction medicine specialists have echoed those concerns, citing research involving heavy adolescent cannabis use, cannabis use disorder, impaired driving, emergency department visits related to high-potency products, and possible mental health risks among vulnerable populations. These experts stress that greater scientific acceptance should be accompanied by stronger consumer protections, standardized labeling, potency limits, and continued investment in prevention and education.
Former DEA Officials Warn Against Weakening Federal Oversight
Some retired Drug Enforcement Administration officials have questioned whether the Department of Health and Human Services gave sufficient weight to abuse potential during its scientific review. Critics argue that cannabis remains significantly different from FDA-approved Schedule III medications because plant-based marijuana products vary widely in potency, cannabinoid composition, and methods of consumption.
Others have warned that moving cannabis to Schedule III could create public confusion by suggesting that all cannabis products have been federally approved as medicines, when in reality the FDA approval process for medications remains separate from the Controlled Substances Act scheduling process.
Supporters of rescheduling largely disagree with that assessment, arguing that the public already distinguishes between state-regulated cannabis products and FDA-approved prescription drugs.
Republicans Remain Divided
Cannabis policy has increasingly become an issue that cuts across traditional political lines. Some Republican lawmakers continue opposing broader legalization, emphasizing public safety, impaired driving, youth access, workplace safety, and concerns about expanding another commercial intoxicant.
These lawmakers generally argue that Congress, not federal agencies, should determine major changes to national drug policy.
Others within the Republican Party have adopted a more states’ rights approach.
These lawmakers maintain that individual states should retain authority to determine cannabis policy without federal interference. Some also support banking reform and tax modernization for state-licensed cannabis businesses, even if they remain skeptical of nationwide legalization.
Business-oriented conservatives have additionally argued that current federal tax policy unfairly penalizes legal businesses operating under state law while allowing illicit operators to remain more competitive.
Democrats Largely Support Reform, but Not Always the Same Reform
Most Democratic lawmakers have supported some form of cannabis reform during the past decade.
However, differences remain regarding how extensive that reform should become.
Moderate Democrats generally view Schedule III as a practical first step that aligns federal policy with current medical evidence while preserving federal oversight.
Progressive Democrats, meanwhile, have argued that rescheduling alone does not adequately address broader issues involving criminal justice reform, social equity, expungement of prior marijuana convictions, banking access, interstate commerce, and the ongoing conflict between federal prohibition and state legalization.
Several Democratic governors overseeing legal cannabis markets have also encouraged Congress to establish comprehensive federal legislation rather than relying exclusively on administrative rulemaking.
Financial Markets Watching Closely
Wall Street has followed the DEA proceedings with considerable interest. Publicly traded cannabis companies have experienced significant stock volatility whenever major federal developments occur.
Investment analysts generally believe that Schedule III would improve financial performance for many cannabis operators primarily because of potential relief from Internal Revenue Code Section 280E.
The tax savings could increase:
- net income
- operating cash flow
- expansion opportunities
- acquisitions
- research investment
- hiring
Some analysts estimate that several large multi-state operators could immediately report substantially stronger earnings if ordinary business deductions become available.
However, investors also recognize that many structural challenges would remain.
These include:
- limited banking access
- restrictions on interstate commerce
- fragmented state regulations
- oversupply in several western states
- continued federal criminal prohibition outside authorized channels
For that reason, many financial experts describe Schedule III as an important catalyst rather than a complete solution.
Banking Reform Still Faces Congressional Action
One common misconception is that rescheduling would immediately allow cannabis businesses full access to traditional banking. Legal experts caution that this is unlikely. Although many financial institutions already provide limited services under existing federal guidance, comprehensive banking protections would still depend largely on congressional legislation or additional regulatory action.
Banks continue evaluating:
- anti-money laundering requirements
- federal compliance obligations
- insurance considerations
- examiner expectations
- reputational risk
Consequently, many cannabis operators may continue relying on specialized financial institutions even if marijuana is ultimately transferred to Schedule III.
Looking Beyond the Hearings
Regardless of the DEA’s ultimate decision, cannabis policy continues evolving at both the federal and state levels.
More than three dozen states now permit medical cannabis programs, while nearly half the country has legalized adult-use recreational marijuana in some form.
Public opinion surveys have consistently shown majority support for legalization, although voters continue expressing differing views regarding regulation, taxation, advertising, potency limits, and social equity initiatives.
For many observers, the current hearings represent more than a scheduling debate. They symbolize the federal government’s attempt to reconcile decades-old drug policy with a rapidly changing landscape in medicine, public opinion, state law, and commercial cannabis markets.
Whether that reconciliation ultimately succeeds remains one of the most closely watched regulatory questions facing the cannabis industry today.
Colorado’s Cannabis Industry Faces a New Chapter if Federal Rescheduling Moves Forward
Colorado has long stood at the forefront of legal cannabis in the United States. As one of the first two states to legalize adult-use marijuana in 2012, Colorado helped establish the regulatory framework that many other states have since adopted. Over the past decade, the industry has generated billions of dollars in retail sales, created tens of thousands of jobs, and contributed significant tax revenue for public education, infrastructure, behavioral health programs, and local governments.
Yet Colorado’s mature cannabis market has also experienced mounting challenges in recent years. Increased competition from newer adult-use markets, declining wholesale flower prices, market saturation, rising operating costs, and continued federal tax burdens have compressed profit margins for cultivators, manufacturers, and retailers alike.
Many Colorado operators view the proposed move from Schedule I to Schedule III as one of the most meaningful federal policy changes since legalization.
Tax Relief Could Strengthen Colorado Businesses
For many Colorado cannabis companies, the most immediate impact would likely come from changes to federal taxation. Under current law, most state-licensed cannabis businesses are subject to Internal Revenue Code Section 280E, which prevents companies trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses.
While businesses can generally deduct the cost of goods sold, they cannot typically deduct expenses such as:
- Employee wages
- Rent and mortgage interest
- Marketing and advertising
- Utilities
- Insurance
- Professional services
- Administrative overhead
As a result, some Colorado operators report effective federal tax rates far above those faced by similarly sized businesses in other industries.
If cannabis is ultimately placed in Schedule III, many tax professionals expect compliant state-licensed operators to become eligible to claim ordinary business deductions, substantially lowering their federal tax liability.
For smaller independent dispensaries and family-owned cultivation operations, those savings could improve cash flow, support hiring, modernize facilities, and reduce the financial pressure that has forced many businesses to consolidate or close.
Increased Investment Could Encourage Innovation
Colorado has long been recognized as a center for cannabis entrepreneurship. The state is home to experienced cultivators, extraction specialists, infused-product manufacturers, testing laboratories, packaging companies, agricultural technology firms, and cannabis software developers.
Industry analysts believe that greater regulatory certainty could attract additional private investment into Colorado-based companies, particularly those focused on research, advanced cultivation technologies, sustainability, and product innovation.
Access to lower tax burdens may also enable businesses to invest in:
- Automation and cultivation efficiency
- Energy-saving technologies
- Water conservation systems
- Advanced genetics and breeding programs
- Consumer product development
- Employee training and retention
While traditional institutional investment may remain cautious until broader federal reforms are enacted, many observers believe Schedule III could improve investor confidence in established operators with strong compliance records.
Research Opportunities Could Expand
Colorado is already home to universities, medical centers, and private research organizations studying cannabinoids and cannabis-related therapies. Researchers have frequently cited federal regulatory barriers as obstacles to conducting large-scale clinical trials involving cannabis.
If Schedule III reduces administrative hurdles for approved research, Colorado institutions may be well positioned to expand investigations into:
- Chronic pain management
- Neurological disorders
- Epilepsy
- Post-traumatic stress disorder (PTSD)
- Sleep disorders
- Cancer symptom management
- Substance use treatment
- Public health outcomes
Expanded research could also strengthen collaboration between academic institutions, healthcare providers, biotechnology companies, and the state’s cannabis industry.
Competition Will Continue Intensifying
Despite optimism surrounding rescheduling, Colorado businesses understand that many existing challenges will remain. The state now competes with numerous adult-use cannabis markets across the country, reducing the tourism advantage it once enjoyed.
Consumers in many regions no longer need to travel to Colorado to purchase legal cannabis, and price competition has intensified as additional states have legalized.
Industry leaders also point to ongoing issues such as:
- Persistent illicit market activity
- Price compression
- Local licensing restrictions
- Workforce shortages in specialized roles
- Rising compliance costs
- Consumer demand for lower-priced products
Because rescheduling alone would not legalize interstate commerce, Colorado cultivators would still be unable to ship products across state lines under current federal law. That limitation continues to restrict market expansion and economies of scale.
Cannabis Tourism Could Benefit Indirectly
Colorado has built an international reputation as a destination for outdoor recreation, craft beverages, culinary experiences, and legal cannabis.
While Schedule III would not immediately change tourism regulations, industry observers believe that increased federal acceptance of medical cannabis could gradually reduce stigma surrounding cannabis travel and wellness experiences.
Businesses offering cannabis-friendly lodging, educational tours, culinary events, and wellness services may benefit if broader public perception continues shifting toward regulated, responsible cannabis use.
A Measured Step Toward Federal Reform
Many Colorado business owners emphasize that rescheduling should be viewed as progress rather than a final destination. Key federal issues, including interstate commerce, banking access, comprehensive tax reform, FDA oversight, and national legalization, would remain unresolved. Nevertheless, many see Schedule III as a meaningful acknowledgment that federal cannabis policy is evolving alongside scientific research, public opinion, and state regulatory systems.
For Colorado, whose cannabis industry has spent more than a decade operating under conflicting federal and state laws, even incremental regulatory changes could improve financial stability and encourage the next generation of innovation.
The Bottom Line
The DEA’s consideration of moving cannabis from Schedule I to Schedule III represents one of the most consequential federal cannabis policy debates in decades. Although the proposal would not legalize marijuana nationwide, it could significantly alter the economic and regulatory landscape for state-licensed cannabis businesses.
Supporters argue that rescheduling reflects current scientific evidence, expands research opportunities, reduces burdensome taxation, and brings federal policy closer to the realities of modern state-regulated cannabis markets.
Opponents caution that additional scientific study, stronger public health protections, and careful regulatory oversight remain essential before making substantial changes to federal drug policy.
For Colorado, the stakes are especially high. As one of the nation’s most established cannabis markets, the state stands to benefit from potential tax relief, expanded research opportunities, and renewed investor confidence. At the same time, longstanding challenges, including intense competition, pricing pressure, and unresolved federal restrictions, will continue to shape the industry’s future. Whatever the DEA ultimately decides, the current hearings underscore a broader shift in the national conversation. Cannabis policy is no longer centered solely on legalization versus prohibition. Increasingly, the debate focuses on how best to regulate a mature, multibillion-dollar industry while balancing public health, economic opportunity, scientific advancement, and state autonomy.
Frequently Asked Questions
Will moving cannabis to Schedule III make recreational marijuana federally legal?
No. Rescheduling would recognize accepted medical use under federal law but would not legalize recreational marijuana nationwide or override existing federal restrictions on interstate commerce.
What is IRS Section 280E?
Section 280E is a provision of the Internal Revenue Code that generally prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. If cannabis is moved to Schedule III, many legal analysts believe compliant state-licensed businesses would no longer be subject to these limitations.
Would cannabis businesses be able to use traditional banks?
Not automatically. While rescheduling may improve the regulatory environment, comprehensive banking access will likely require additional congressional action or updated federal guidance.
How could Colorado benefit from cannabis rescheduling?
Potential benefits include lower federal tax burdens, improved business profitability, increased investment, expanded research opportunities, and greater long-term industry stability. However, challenges such as interstate commerce restrictions and market competition would remain.
Is federal legalization the same as rescheduling?
No. Rescheduling changes cannabis’s classification under the Controlled Substances Act. Federal legalization would require broader statutory or regulatory changes governing production, distribution, possession, and commerce across the United States.
